Business Description
Annexon Inc
NAICS : 541714
SIC : 2834
ISIN : US03589W1027
Share Class Description:
ANNX: Ordinary SharesTotal Employee Number:
93Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.85 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.3 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year FCF Growth Rate | 18.8 | |||||
3-Year Book Growth Rate | -33.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 61.56 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.48 | |||||
9-Day RSI | 53.32 | |||||
14-Day RSI | 54.04 | |||||
3-1 Month Momentum % | -28.59 | |||||
6-1 Month Momentum % | -25.54 | |||||
12-1 Month Momentum % | 88.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.35 | |||||
Quick Ratio | 6.35 | |||||
Cash Ratio | 6.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46.3 | |||||
Shareholder Yield % | -3.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -96.27 | |||||
ROA % | -73.47 | |||||
ROIC % | -481.17 | |||||
3-Year ROIIC % | -2808.73 | |||||
ROC (Joel Greenblatt) % | -767.57 | |||||
ROCE % | -89.87 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.68 | |||||
Price-to-Tangible-Book | 4.67 | |||||
EV-to-EBIT | -3.73 | |||||
EV-to-EBITDA | -3.78 | |||||
EV-to-Forward-Revenue | 8.48 | |||||
EV-to-FCF | -4.18 | |||||
| Price-to-Net-Current-Asset-Value | 5.61 | |||||
| Price-to-Net-Cash | 5.72 | |||||
Earnings Yield (Greenblatt) % | -26.81 | |||||
FCF Yield % | -18.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annexon Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.22 | ||
| Beta | 2.0625 | ||
| 3-Year Sharpe Ratio | 0.51 | ||
| 3-Year Sortino Ratio | 0.98 | ||
| Volatility % | 68.52 | ||
| 14-Day RSI | 54.04 | ||
| 14-Day ATR ($) | 0.471676 | ||
| 20-Day SMA ($) | 5.602 | ||
| 12-1 Month Momentum % | 88.33 | ||
| 52-Week Range ($) | 2.03 - 7.18 | ||
| Shares Outstanding (Mil) | 163.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annexon Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annexon Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 28 days | ||
| General meeting for 2026 | 2026-06-11 08:00 | 4.72 (-8.35%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 5.12 (-5.01%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:40 | 5.26 (-3.84%) | ||
| Guidance call for 2026 | 2026-05-13 11:20 | 5.44 (-3.20%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 5.70 (-1.72%) | ||
| the 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 11:45 | 5.80 (-1.02%) | ||
| Annual report for 2025 | 2026-03-30 | 5.00 (-3.66%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 5.00 (-3.66%) |
Show
Entries
Annexon Inc Frequently Asked Questions
What is Annexon Inc(ANNX)'s stock price today?
The current price of ANNX is $5.89. The 52 week high of ANNX is $7.18 and 52 week low is $2.03.
When is next earnings date of Annexon Inc(ANNX)?
The next earnings date of Annexon Inc(ANNX) is 2026-08-14 Est..
Does Annexon Inc(ANNX) pay dividends? If so, how much?
Annexon Inc(ANNX) does not pay dividend.
Guru Commentaries on NAS:ANNX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Annexin Pharmaceuticals, Ardelyx, Fusion Pharmaceuticals, Aurora Technology Acquisition, or Terran Orbital? | 2023-12-21 |
Articles on Annexon Inc
Headlines
See More- 1
Jul 15, 2026
At a glance: stocks gapping up premarket
Seeking Alpha • 6:34am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers